Cargando…

Advanced PSMA-PET/CT Imaging Parameters in Newly Diagnosed Prostate Cancer Patients for Predicting Metastatic Disease

SIMPLE SUMMARY: Prostate cancer is among the most common malignancies in men worldwide. Many patients undergo a PSMA-PET/CT study for staging assessment. The aim of this retrospective study was to evaluate the relationship between advanced imaging parameters such as prostate PSMA tumor volume and th...

Descripción completa

Detalles Bibliográficos
Autores principales: Yechiel, Yaniv, Orr, Yaly, Gurevich, Konstantin, Gill, Ronit, Keidar, Zohar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9954788/
https://www.ncbi.nlm.nih.gov/pubmed/36831365
http://dx.doi.org/10.3390/cancers15041020
_version_ 1784894199644028928
author Yechiel, Yaniv
Orr, Yaly
Gurevich, Konstantin
Gill, Ronit
Keidar, Zohar
author_facet Yechiel, Yaniv
Orr, Yaly
Gurevich, Konstantin
Gill, Ronit
Keidar, Zohar
author_sort Yechiel, Yaniv
collection PubMed
description SIMPLE SUMMARY: Prostate cancer is among the most common malignancies in men worldwide. Many patients undergo a PSMA-PET/CT study for staging assessment. The aim of this retrospective study was to evaluate the relationship between advanced imaging parameters such as prostate PSMA tumor volume and the presence of metastatic disease in newly diagnosed prostate cancer patients undergoing PSMA-PET/CT for staging purposes. PSMA-PET/CT of 85 patients was analyzed, and these advanced imaging parameters were found to be statistically capable of assessing the likelihood of the presence of metastatic disease. ABSTRACT: (1) Purpose: Recent studies indicate that advanced imaging parameters such as prostate PSMA tumor volume may have a value in predicting response to treatment of castration-resistant prostate cancer patients. In this study, we examine whether a relationship can be found between advanced imaging parameters such as prostate PSMA-TV and the presence of metastatic disease in newly diagnosed prostate cancer patients undergoing PSMA-PET/CT for staging purposes; (2) Methods: We retrospectively analyzed PET/CT studies of 91 patients with newly diagnosed prostate cancer. Prostate PSMA-TV was measured using the MIRADA-XD software. PET/CT results were recorded, as well as additional clinical parameters such as the Gleason score, etc.; (3) Results: Prostate PSMA-TV measurements were found to be able to significantly differentiate metastatic from the non-metastatic patient groups (13.7 vs. 5.5, p-value < 0.05). Overall, 54% percent of patients with levels of over 8.1 PSMA-TV had metastatic lesions found on their PSMA-PET/CT. A model based on this cutoff attained a sensitivity of 80%, a specificity of 68.3%, and a negative predictive value of 93.5% for identifying metastatic disease. Another bin model was found statistically capable of assessing the likelihood of the presence of metastatic disease with a p-value of 0.001; (4) Conclusions: Prostate PSMA-TV measurement has the potential to predict the presence of metastatic disease at staging and thus may impact further treatment decision and patient management.
format Online
Article
Text
id pubmed-9954788
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99547882023-02-25 Advanced PSMA-PET/CT Imaging Parameters in Newly Diagnosed Prostate Cancer Patients for Predicting Metastatic Disease Yechiel, Yaniv Orr, Yaly Gurevich, Konstantin Gill, Ronit Keidar, Zohar Cancers (Basel) Article SIMPLE SUMMARY: Prostate cancer is among the most common malignancies in men worldwide. Many patients undergo a PSMA-PET/CT study for staging assessment. The aim of this retrospective study was to evaluate the relationship between advanced imaging parameters such as prostate PSMA tumor volume and the presence of metastatic disease in newly diagnosed prostate cancer patients undergoing PSMA-PET/CT for staging purposes. PSMA-PET/CT of 85 patients was analyzed, and these advanced imaging parameters were found to be statistically capable of assessing the likelihood of the presence of metastatic disease. ABSTRACT: (1) Purpose: Recent studies indicate that advanced imaging parameters such as prostate PSMA tumor volume may have a value in predicting response to treatment of castration-resistant prostate cancer patients. In this study, we examine whether a relationship can be found between advanced imaging parameters such as prostate PSMA-TV and the presence of metastatic disease in newly diagnosed prostate cancer patients undergoing PSMA-PET/CT for staging purposes; (2) Methods: We retrospectively analyzed PET/CT studies of 91 patients with newly diagnosed prostate cancer. Prostate PSMA-TV was measured using the MIRADA-XD software. PET/CT results were recorded, as well as additional clinical parameters such as the Gleason score, etc.; (3) Results: Prostate PSMA-TV measurements were found to be able to significantly differentiate metastatic from the non-metastatic patient groups (13.7 vs. 5.5, p-value < 0.05). Overall, 54% percent of patients with levels of over 8.1 PSMA-TV had metastatic lesions found on their PSMA-PET/CT. A model based on this cutoff attained a sensitivity of 80%, a specificity of 68.3%, and a negative predictive value of 93.5% for identifying metastatic disease. Another bin model was found statistically capable of assessing the likelihood of the presence of metastatic disease with a p-value of 0.001; (4) Conclusions: Prostate PSMA-TV measurement has the potential to predict the presence of metastatic disease at staging and thus may impact further treatment decision and patient management. MDPI 2023-02-06 /pmc/articles/PMC9954788/ /pubmed/36831365 http://dx.doi.org/10.3390/cancers15041020 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Yechiel, Yaniv
Orr, Yaly
Gurevich, Konstantin
Gill, Ronit
Keidar, Zohar
Advanced PSMA-PET/CT Imaging Parameters in Newly Diagnosed Prostate Cancer Patients for Predicting Metastatic Disease
title Advanced PSMA-PET/CT Imaging Parameters in Newly Diagnosed Prostate Cancer Patients for Predicting Metastatic Disease
title_full Advanced PSMA-PET/CT Imaging Parameters in Newly Diagnosed Prostate Cancer Patients for Predicting Metastatic Disease
title_fullStr Advanced PSMA-PET/CT Imaging Parameters in Newly Diagnosed Prostate Cancer Patients for Predicting Metastatic Disease
title_full_unstemmed Advanced PSMA-PET/CT Imaging Parameters in Newly Diagnosed Prostate Cancer Patients for Predicting Metastatic Disease
title_short Advanced PSMA-PET/CT Imaging Parameters in Newly Diagnosed Prostate Cancer Patients for Predicting Metastatic Disease
title_sort advanced psma-pet/ct imaging parameters in newly diagnosed prostate cancer patients for predicting metastatic disease
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9954788/
https://www.ncbi.nlm.nih.gov/pubmed/36831365
http://dx.doi.org/10.3390/cancers15041020
work_keys_str_mv AT yechielyaniv advancedpsmapetctimagingparametersinnewlydiagnosedprostatecancerpatientsforpredictingmetastaticdisease
AT orryaly advancedpsmapetctimagingparametersinnewlydiagnosedprostatecancerpatientsforpredictingmetastaticdisease
AT gurevichkonstantin advancedpsmapetctimagingparametersinnewlydiagnosedprostatecancerpatientsforpredictingmetastaticdisease
AT gillronit advancedpsmapetctimagingparametersinnewlydiagnosedprostatecancerpatientsforpredictingmetastaticdisease
AT keidarzohar advancedpsmapetctimagingparametersinnewlydiagnosedprostatecancerpatientsforpredictingmetastaticdisease